| Literature DB >> 34906288 |
Kristine Shik Luk, Yat-Ming Tsang, Alex Yat-Man Ho, Wing-Kin To, Ben Kwok-Ho Wong, Maureen Mo-Lin Wong, Yiu-Chung Wong.
Abstract
During March 2016-January 2019, Burkholderia cepacia complex (BCC) infection developed in 13 persons who inject drugs (PWID) in Kowloon West Region, Hong Kong, China. Seven cases were infective spondylitis, 2 endocarditis, 2 septic arthritis, 1 intramuscular abscess and bacteremia, and 1 necrotizing fasciitis. Pulsed-field gel electrophoresis revealed that the isolates from 9 patients were clonally related. This clone caused major illness, and 11 of the 13 patients required surgical treatment. Clinicians should be aware of this pathogen and the appropriate broad-spectrum antimicrobial drugs to empirically prescribe for PWID with this life-threatening infection. Close collaboration among public health authorities, outreach social workers, and methadone clinics is essential for timely prevention and control of outbreaks in the PWID population.Entities:
Keywords: Burkholderia; Burkholderia cepacia complex; Hong Kong; bacteria; disease outbreak; drug users; persons who inject drugs; pulsed-field gel electrophoresis
Mesh:
Year: 2021 PMID: 34906288 PMCID: PMC8798689 DOI: 10.3201/eid2802.210945
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Clinical features of invasive infections caused by Burkholderia cepacia complex in persons who inject drugs, Hong Kong, China, 2016–2019
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
| 51/F | Diabetes mellitus, hepatitis C | Back pain lower limb numbness and weakness (3) | 98.2 (36.8) | D | T11/12 spondylodiscitis with cord compression |
|
| 66/M | Hepatitis C | Back pain (20) | 97.9 (36.6) | E | L4/5 spondylodiscitis |
|
| 66/M | Hepatocellular carcinoma, hepatitis C | Right upper limb numbness and weakness (60) | 98.8 (37.1) | D | C5/6, C6/7 spondylodiscitis with prevertebral abscess |
|
| 65/M | Deep vein thrombosis, pseudo-aneurysm, right above-knee amputation, hepatitis C | Reduced general condition, dizziness and vomiting (1) | 99.3 (37.4) | NA | Endocarditis and septic emboli in lungs |
|
| 60/M | Schizophrenia, deep vein thrombosis, pseudo-aneurysm, hepatitis C | Fever, right leg pain and redness (1) | 103.1 (39.5) | NA | Intramuscular abscess and bacteremia† |
|
| 59/M | Gout | Back pain and bilateral foot numbness (7) | 98.4 (36.9) | E | L5/S1 spondylodiscitis |
|
| 51/F | Psoas abscess, deep vein thrombosis, fractured right hip with open fixation, hepatitis C | Right hip pain, not able to bear weight (7) | 99.0 (37.2) | NA | Right hip prosthetic joint infection and osteomyelitis |
|
| 69/M | Asthma, infective spondylodiscitis | Right knee pain (3) | 101.1 (38.4) | NA | Right knee septic arthritis and intramuscular abscess† |
|
| 62/M | Stroke, hepatitis B, hepatitis C | Fever, back pain, right lower limb numbness, and tingling sensation (4) | 99.1 (37.3) | E | L3/4, L5/S1 spondylodiscitis |
|
| 64/M | Stroke, deep vein thrombosis, infective cervical spondylitis, hepatitis C | Back pain with radiation to right lateral thigh and weakness (3) | 99.3 (37.4) | D | L2/3 spondylodiscitis |
|
| 46/M | Esophageal cancer, hepatitis C | Fever, drowsiness, cough, dyspnea (1) | 103.3 (39.6) | NA | Endocarditis and septic emboli in brain† |
|
| 66/M | Infective endocarditis, hepatitis C | Back pain and lower limb weakness (14) | 98.2 (36.8) | D | L1/2 spondylodiscitis with cord compression |
|
| 55/M | Hepatitis C | Left knee and thigh pain (2) | 96.8 (36) | NA | Left thigh intramuscular abscess and necrotizing fasciitis† |
*ASIA impairment scale: A = complete (no motor or sensory function in S4–S5); B = incomplete (sensory function below neurologic level and in S4–S5, no motor function below neurologic level); C = incomplete (motor function is preserved below neurologic level, and more than half of the key muscle groups below neurologic level have a muscle grade <3); D = incomplete (motor function is preserved below neurologic level, and at least half of the key muscle groups below neurologic level have a muscle grade 3); E = normal. ASIA, American Spinal Injury Association; NA, not applicable. †Polymicrobial infection:
Laboratory and microbiological findings, treatments, and outcomes of invasive infections caused by Burkholderia cepacia complex in persons who inject drugs, Hong Kong, China, 2016–2019*
| Variable | Finding |
| Median leukocytes, × 109 cells/L (range) | 9.2 (3.94–24.7) |
| Median ESR, mm/h (range) | 79.5 (43 to >120) |
| Median CRP, mg/L (range) | 68 (21 to >294) |
| Empirical antimicrobial therapy (no. patients) | Amoxicillin/clavulanate (10); cloxacillin (3); vancomycin (2); ampicillin, cefoperazone/sulbactam, gentamicin, piperacillin/tazobactam (1) |
| Definitive antimicrobial therapy (no. patients) | Trimethoprim/sulfamethoxazole (6); ceftazidime (5); levofloxacin (5); meropenem (2); minocycline, piperacillin/tazobactam (1) |
| Median duration of antimicrobial therapy (range), wk | 6 (1–12) |
| Surgery (no. patients) | Vertebral disk excision (3), incision and drainage (1), spinal fusion† (3), joint arthrotomy (2), excisional arthroplasty (1) |
| Positive culture (no. patients) | Bone (5), blood† (4), intervertebral disk (3), abscess (2), joint fluid (1) |
| Median length of stay (range), d | 43 (11 – 97) |
| Death (d after first visit) | Patient 3 (124); patient 4 (13) |
*CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. †Patient 2 had a relapse of Burkholderia cepacia complex infective spondylitis 5 mo after receiving meropenem and oral trimethoprim/sulfamethoxazole for 6 wk; spinal fusion was performed during the relapse episode.
Figure 1Pulsed-field gel electrophoresis of Burkholderia cepacia complex causing invasive infection in 13 persons who inject drugs, Hong Kong, China, 2016–2019.
Figure 2Number of PWID with newly detected BCC invasive infection, by clonal types per year, Hong Kong, China, 2016 through June 30, 2019. PWID, persons who inject drugs; BCC, Burkholderia cepacia complex.